Kura Oncology, Inc. (NASDAQ:KURA) Sees Large Decrease in Short Interest

Kura Oncology, Inc. (NASDAQ:KURA) was the target of a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 9,290,000 shares, a decline of 8.8% from the September 30th total of 10,190,000 shares. Approximately 14.3% of the company’s stock are short sold. Based on an average daily volume of 545,700 shares, the days-to-cover ratio is presently 17.0 days.

Institutional Investors Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the business. nVerses Capital LLC bought a new stake in shares of Kura Oncology during the third quarter valued at about $25,000. SG Americas Securities LLC bought a new stake in Kura Oncology during the 1st quarter worth approximately $110,000. Quarry LP purchased a new stake in Kura Oncology in the 2nd quarter worth approximately $196,000. Entropy Technologies LP bought a new position in Kura Oncology in the 1st quarter valued at $218,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Kura Oncology by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock worth $288,000 after buying an additional 5,788 shares in the last quarter.

Kura Oncology Trading Down 1.5 %

Shares of Kura Oncology stock opened at $16.72 on Friday. The stock has a market capitalization of $1.27 billion, a P/E ratio of -7.71 and a beta of 0.84. Kura Oncology has a 52-week low of $7.92 and a 52-week high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94. The stock’s 50-day simple moving average is $19.18 and its 200 day simple moving average is $20.03.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.04. The firm’s revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.53) earnings per share. As a group, research analysts anticipate that Kura Oncology will post -2.46 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on KURA shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th. Wedbush restated an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research note on Friday, August 9th. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. JMP Securities restated a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. Finally, Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $26.00 to $19.00 in a report on Monday, October 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.